Clinical trials: Primary Erythromelalgia
- Condition Primary Erythromelalgia
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Inherited Erythromelalgia
Evaluation Of The Efficacy And Safety Of Single Doses Of PF-05089771 In Patients With Primary (Inherited) Erythromelalgia
The purpose of this study is to evaluate the efficacy and safety of single doses of PF-05089771 against placebo in treatment of pain in patients with primary, inherited erythromelalgia.
- Trial name
- IEM (NCT01769274)
- Testing
- PF-05089771
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Pfizer
Primary Erythromelalgia, Inherited Erythromelalgia
Phase 2a, Exploratory Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of XPF-002 in Patients With Primary/Inherited Erythromelalgia
This is a Phase 2a single-center, randomized, double-blind, Placebo-controlled, parallel group study with XPF-002 applied twice daily over 14 or 21 days in patients with Primary/Inherited Erythromelalgia (IEM).
- Trial name
- NCT01486446
- Testing
- XPF-002
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Xenon Pharmaceuticals Inc.